Nantahala Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Nantahala Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.78M	Hold	2,000,000	–	–	0.1%	124
2025 Q4	$3.22M	Hold	2,000,000	–	–	0.11%	118
2025 Q3	$5.46M	Hold	2,000,000	–	–	0.19%	101
2025 Q2	$7.28M	Hold	2,000,000	–	–	0.29%	69
2025 Q1	$3.84M	Buy	+2,000,000	New	+$4.08M	0.15%	84
2022 Q1	–	Sell	-4,918,565	Closed	-$10.5M	–	124
2021 Q4	$11.1M	Sell	4,918,565 -59,630	-1%	-$163K	0.39%	52
2021 Q3	$14.3M	Sell	4,978,195 -191,868	-4%	-$548K	0.45%	53
2021 Q2	$19.6M	Buy	5,170,063 +19,244	+0.4%	+$64.8K	0.56%	42
2021 Q1	$17.4M	Sell	5,150,819 -1,889,668	-27%	-$6.81M	0.51%	45
2020 Q4	$19.7M	Buy	7,040,487 +1,293,864	+23%	+$3.78M	0.61%	43
2020 Q3	$14.4M	Sell	5,746,623 -354,488	-6%	-$3.11M	0.44%	52
2020 Q2	$82.9M	Sell	6,101,111 -458,367	-7%	-$4.74M	2.5%	7
2020 Q1	$49.7M	Sell	6,559,478 -177,642	-3%	-$1.38M	1.86%	10
2019 Q4	$42.6M	Buy	6,737,120 +947,559	+16%	+$4.5M	1.31%	21
2019 Q3	$22.7M	Hold	5,789,561	–	–	0.84%	31
2019 Q2	$28M	Buy	5,789,561 +848,500	+17%	+$4.83M	0.86%	31
2019 Q1	$40.5M	Sell	4,941,061 -123,028	-2%	-$844K	1.26%	20
2018 Q4	$28M	Buy	5,064,089 +339,878	+7%	+$2.66M	0.86%	30
2018 Q3	$41.7M	Buy	4,724,211 +201,100	+4%	+$1.8M	1.12%	26
2018 Q2	$45.1M	Buy	4,523,111 +1,136,968	+34%	+$11.4M	1.83%	18
2018 Q1	$32.3M	Buy	3,386,143 +1,452,276	+75%	+$20.3M	1.45%	20
2017 Q4	$28.8M	Buy	1,933,867 +565,920	+41%	+$9.39M	1.28%	19
2017 Q3	$26.9M	Sell	1,367,947 -780,676	-36%	-$12M	1.32%	17
2017 Q2	$30.9M	Sell	2,148,623 -131,908	-6%	-$1.67M	2.45%	14
2017 Q1	$21M	Buy	2,280,531 +48,123	+2%	+$470K	2.34%	12
2016 Q4	$23.2M	Buy	2,232,408 +317,400	+17%	+$2.73M	2.41%	12
2016 Q3	$17.3M	Buy	1,915,008 +234,618	+14%	+$1.99M	2.09%	14
2016 Q2	$12.6M	Buy	1,680,390 +333,064	+25%	+$2.91M	1.36%	21
2016 Q1	$12.1M	Buy	1,347,326 +1,125,652	+508%	+$9.13M	1.25%	22
2015 Q4	$2.86M	Buy	+221,674	New	+$2.26M	0.37%	51

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nantahala Capital Management's AKBA Position: Q1 2026 in Review

Nantahala Capital Management held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 2,000,000 shares worth $2.78M. The position accounts for 0.1% of the portfolio, ranked #124.

Nantahala Capital Management first reported a position in AKBA in Q4 2015 and has held it in 30 quarters since. The position peaked at $82.9M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Nantahala Capital Management held 2,000,000 shares of Akebia Therapeutics worth $2.78M as of Q1 2026.
Nantahala Capital Management left its Akebia Therapeutics share count unchanged in Q1 2026.
Akebia Therapeutics made up 0.1% of Nantahala Capital Management's portfolio in Q1 2026, its #124 holding.
Nantahala Capital Management first reported a position in Akebia Therapeutics in Q4 2015 and has held it in 30 quarters since.
Nantahala Capital Management's Akebia Therapeutics position peaked at $82.9M in Q2 2020.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.